These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22918794)

  • 41. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
    Eriksson B
    Curr Opin Oncol; 2010 Jul; 22(4):381-6. PubMed ID: 20473165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pancreatic neuroendocrine tumors: does chemotherapy work?
    Tejani MA; Saif MW
    JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of a new isolated metastasis during sunitinib treatment in renal cell carcinoma patients: a lesson from two cases.
    Shablak A; O'Dwyer J; Hawkins R; Board R
    Urol Int; 2011; 86(2):245-8. PubMed ID: 21124010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):158-60. PubMed ID: 22780939
    [No Abstract]   [Full Text] [Related]  

  • 46. Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
    Mankal P; O'Reilly E
    Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
    BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME; Uomo I; Pastorello M
    JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
    Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
    Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
    Shea YF; Chiu WY; Mok MY; Hung IF; Yau CC
    J Clin Pharm Ther; 2013 Aug; 38(4):327-9. PubMed ID: 23586819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED; Raymond E
    BioDrugs; 2011 Oct; 25(5):307-16. PubMed ID: 21942915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T; Roukos DH
    Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract]   [Full Text] [Related]  

  • 56. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
    Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E
    J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic and palliative options for diffuse neuroendocrine metastatic disease.
    Holen K
    J Gastrointest Surg; 2006 Mar; 10(3):337-40. PubMed ID: 16622986
    [No Abstract]   [Full Text] [Related]  

  • 58. New treatment options with cytotoxic agents in neuroendocrine tumours.
    Hammel P; Hentic O; Neuzillet C; Faivre S; Raymond E; Ruszniewski P
    Target Oncol; 2012 Sep; 7(3):169-72. PubMed ID: 22911013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):392-5. PubMed ID: 20203442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.